Table 2.
Characteristics of patients with mRCC undergoing anti-VEGF-based therapy.
| n (%) | |
|---|---|
| Total cases | 18 (100) |
| Histology | |
| ccRCC | 16 (89) |
| Papillary | 1 (6) |
| Chromophobe | 1 (6) |
| Gender | |
| Female | 7 (39) |
| Male | 11 (61) |
| Distant metastasis1 | |
| M0 | 0 |
| M+ | 3 (17) |
| Mx | 15 (83) |
| Lymph node metastasis1 | |
| N0 | 2 (11) |
| N1 | 1 (6) |
| N2 | 1 (6) |
| Nx | 14 (78) |
| T-classification1 | |
| 1 | 1 (6) |
| 1a | 2 (11) |
| 1b | 2 (11) |
| 2a | 2 (11) |
| 3b | 6 (33) |
| 4 | 2 (11) |
| x | 3 (17) |
| Differentiation | |
| G1 | 0 (0) |
| G2 | 12 (67) |
| G3 | 6 (33) |
| TKI-first line | |
| Sunitinib | 12 (67) |
| Sorafenib | 4 (22) |
| Bevacizumab | 1 (6) |
| Axitinib | 1 (6) |
| Death within follow-up | |
| No | 4 (22) |
| Yes | 14 (78) |
| Age, median, min-max (y) | 59.5 (48–80) |
| OS, median, min-max (m) | 12.4 (0.8–59.3) |
ccRCC, clear cell renal carcinoma; TKI, tyrosine kinase inhibitor; OS, overall survival; mRCC, metastatic renal cell carcinoma.
*
TNM status refers to the initial histopathological evaluation after nephrectomy.